Novavax COVID-19 Vaccine Phase 3 Clinical Trial in Missouri

The University of Missouri School of Medicine’s Clinical Research Center is taking part in the Phase 3 clinical trial for the Novavax COVID-19 vaccine, with more than 100 participants. The center is one of 115 sites enrolling 30,000 participants. Maryland-based biotechnology company Novavax, Inc. developed the COVID-19 vaccine. Data from the Novavax Phase 3 clinical trial in the U.K. shows 96% efficacy. In that trial, efficacy against the U.K. variant was 86%. The Novavax vaccine is given in two doses, 21 days apart. Two-thirds of trial participants receive the vaccine, one-third receive a placebo. The Novavax COVID-19 vaccine is a protein-based vaccine made from the genetic sequence of SARS-CoV-2, which is the virus that causes COVID-19. It uses a different technology than vaccines made by Pfizer, Moderna and Johnson & Johnson. The vaccine would not require freezing temperatures, which would make it easier to transport and store.

Видео Novavax COVID-19 Vaccine Phase 3 Clinical Trial in Missouri канала HEC Science & Technology